Cargando…

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones

INTRODUCTION: Previous work has shown that besifloxacin, an 8-chloro-fluoroquinolone, has more potent activity against gram-positive pathogens than moxifloxacin and gatifloxacin, which carry an 8-methoxy group. This study was conducted to determine the contribution of the R7 and R8 substituent to fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haas, Wolfgang, Sanfilippo, Christine M, Hesje, Christine K, Morris, Timothy W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647603/ https://www.ncbi.nlm.nih.gov/pubmed/23662042 http://dx.doi.org/10.2147/OPTH.S44085

Ejemplares similares

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
por: Haas, Wolfgang, et al.
Publicado: (2010)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation
por: de Jesus, José Izo Santana da Silva, et al.
Publicado: (2022)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Molecular Epidemiology of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Isolated from the Eye
por: Hesje, Christine K, et al.
Publicado: (2011)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
por: Al Hagbani, Turki, et al.
Publicado: (2023)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
por: Khimdas, S., et al.
Publicado: (2011)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes
por: Schechter, Barry A., et al.
Publicado: (2019)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Torkildsen, Gail, et al.
Publicado: (2010)

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
por: dos Santos, Giselly Almeida, et al.
Publicado: (2020)

Antibacterial Potency of Honey
por: Albaridi, Najla A.
Publicado: (2019)

Synthesis and In-vitro Antibacterial Activities of Acetylanthracene and Acetylphenanthrene Derivatives of Some Fluoroquinolones
por: Shamsa, Fazel, et al.
Publicado: (2011)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra, Ranjan, et al.
Publicado: (2012)

Antibacterial isoamphipathic oligomers highlight the importance of multimeric lipid aggregation for antibacterial potency
por: Brown, Joseph S., et al.
Publicado: (2018)

Mycobacterium Fluoroquinolone Resistance Protein D (MfpD), a GTPase-Activating Protein of GTPase MfpB, Is Involved in Fluoroquinolones Potency
por: Huang, Yu, et al.
Publicado: (2022)

Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin in Different Simulated Body Fluids
por: Singh, C. L., et al.
Publicado: (2015)

Antibacterial Activity of New Dibenzoxepinone Oximes with Fluorine and Trifluoromethyl Group Substituents
por: Limban, Carmen, et al.
Publicado: (2011)

Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance
por: Lungu, Ioana-Andreea, et al.
Publicado: (2022)

Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach
por: Sood, Damini, et al.
Publicado: (2018)

Fluoroquinolone-Based Organic Salts (GUMBOS) with Antibacterial Potential
por: Costa, Fábio M. S., et al.
Publicado: (2023)

Fluoromaticity: The Molecular Orbital Contributions of Fluorine Substituents to the π-Systems of Aromatic Rings
por: Fuhrer, Timothy J., et al.
Publicado: (2021)

Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities
por: Idowu, Temilolu, et al.
Publicado: (2017)

The antibacterial potency and antibacterial mechanism of a commercially available surface‐anchoring quaternary ammonium salt (SAQAS)‐based biocide in vitro
por: Saseendran Nair, Shilpa, et al.
Publicado: (2022)

Antibacterial Potency of an Active Compound from Sansevieria trifasciata Prain: An Integrated In Vitro and In Silico Study
por: Kasmawati, Henny, et al.
Publicado: (2023)

In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus
por: Masadeh, Majed M., et al.
Publicado: (2019)

The Effect of Substituent, Degree of Acetylation and Positioning of the Cationic Charge on the Antibacterial Activity of Quaternary Chitosan Derivatives
por: Sahariah, Priyanka, et al.
Publicado: (2014)

Experimental and Theoretical Study of O-Substituent Effect on the Fluorescence of 8-Hydroxyquinoline
por: Zayed, Mohie E. M., et al.
Publicado: (2015)

Antibacterial Properties of Mesoporous Silica Nanoparticles Modified with Fluoroquinolones and Copper or Silver Species
por: Ugalde-Arbizu, Maider, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5eqsq31l1loqtnlsjt7fc1j4m7